文献速递消化道肿瘤与早癌消化内镜

超声造影通过提高结直肠癌肝转移检出率指导治疗策略

Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases.
PubMed 文献 · J Hepatol · 2020-10-14

该前瞻性研究纳入2015年12月至2019年5月组织学确诊的296例结直肠癌患者,评估超声造影(CEUS)对分期CT后未检出肝转移者的检出价值及治疗策略影响。CEUS额外检出2.7%的结直肠癌肝转移(T3/T4期为4.0%),使75%此类患者肿瘤治疗策略改变;对CT后性质不明的肝局灶性病变,CEUS可判定98.4%病变的良恶性。

要点

  • CEUS在分期CT后额外检出2.7%的结直肠癌肝转移,T3/T4期患者额外检出率为4.0%。
  • CEUS额外检出肝转移的患者中,75%(6/8)的肿瘤治疗策略发生改变。
  • 对CT后性质不明的肝局灶性病变,CEUS可判定98.4%病变的良恶性。

核心结论

  • CEUS总体额外检出2.7%的结直肠癌肝转移(T3/T4期患者为4.0%),并对其中75%患者的肿瘤治疗策略产生显著影响。
  • T3/T4期肿瘤患者可能尤其受益于CEUS检查。
  • 作者提出将CEUS作为CT检出性质不明病变的首选影像学方法。

研究设计与样本

  • 前瞻性分析2015年12月至2019年5月在本三级胃肠病学中心新诊断且组织学确诊的结直肠癌患者。
  • 对分期CT后无结直肠癌肝转移的296例患者使用造影剂(SonoVue®)行CEUS检查。
  • 以MRI或组织学作为参考标准诊断CT漏诊的结直肠癌肝转移,良性肝局灶性病变由MRI或随访CT确认(平均随访间隔18个月)。

主要发现

  • CEUS额外检出8例结直肠癌肝转移,总体为2.7%;敏感度88.9%、特异度99.0%、阳性预测值100%、阴性预测值99.6%。
  • 仅由CEUS检出肝转移的患者均处于T3/T4期,该期额外检出率为4.0%。
  • 需筛查人数在全部患者中为37,在T3/T4期患者中为24.5。
  • 经委员会认证的放射科医师和肿瘤科医师复核后,8例中6例的治疗策略发生改变。
  • 分期CT后62例(20.9%)存在性质不明肝局灶性病变,CEUS判定其中98.4%病变的良恶性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: CT may miss up to 30% of cases of colorectal liver metastases (CRLMs). We assessed the impact of contrast-enhanced ultrasound (CEUS) on the detection of CRLMs and on changes to the therapeutic strategy; additionally, we assessed the accuracy of CEUS in differentiating unclear focal liver lesions (FLLs) compared to staging-CT. METHODS: We prospectively analyzed all patients with newly diagnosed and histologically confirmed colorectal cancer (CRC) at our tertiary gastroenterological center between December 2015 and May 2019. CEUS was performed in a total of 296 patients without CRLMs after staging-CT using the contrast agent (SonoVue®). Standard of reference was obtained by MRI or histology to diagnose CRLMs missed by CT. Benign FLLs were confirmed by MRI or follow-up CT (mean follow-up interval: 18 months). RESULTS: Eight additional CRLMs were detected by CEUS (overall 2.7%; sensitivity 88.9%, specificity 99.0%, positive predictive value 100%, negative predictive value 99.6%). All patients with CRLMs detected only by CEUS were in tumor stage T3/T4 (4.0% additionally detected CRLMs). The number needed to screen to detect 1 additional CRLM by CEUS was 37 in all patients and 24.5 in T3/T4-patients. When results were reviewed by a board-certified radiologist and oncologist, the therapeutic strategy changed in 6 of these 8 patients. Among the 62 patients (20.9%) with unclear FLLs after staging-CT, CEUS determined the dignity (malignant vs. benign) of 98.4% of the FLLs. CONCLUSION: Overall, CEUS detected 2.7% additional CRLMs (including 4.0% in tumor stage T3/T4) with a significant impact on the oncological therapeutic strategy for 75% of these patients. Patients with tumor stage T3/T4 would particularly benefit from CEUS. We propose CEUS as the first imaging modality for CT-detected lesions of unknown dignity. LAY SUMMARY: In patients with newly diagnosed colorectal cancer, contrast-enhanced ultrasound (CEUS) detected additional liver metastases after computed tomography (CT). In the majority of these patients, the oncological therapy was changed after obtaining the CEUS results. After staging-CT, 21% of hepatic lesions remained unclear. In these cases, CEUS was accurate to either reveal or exclude liver metastasis in nearly all patients and could reduce costs (e.g., number of MRI scans).

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Sawatzki M, Güller U, Güsewell S, et al. Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases. J Hepatol. 2020. PMID: 33065168. doi:10.1016/j.jhep.2020.09.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。